Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Alexander Egusquiza

Pulmonary Disease Miami, FL Medical Doctor

NPI 1104276583 CMS profile 2570978

7000 Sw 97Th Ave Ste 120, Miami, FL 33173

Open in the dashboard

General payments

$6,916

252 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexander Egusquiza of Miami, FL is reported in the CMS Open Payments database as having received $6,916 across 252 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,729 94
2024 General $2,859 111
2023 General $1,203 46
2022 General $124 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexander Egusquiza
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Alexander Egusquiza were reported at $2,729. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Alexander Egusquiza Pulmonary Disease median Middle half National median
2019 $0 $377 $109–$1,340 $163
2020 $0 $230 $56–$907 $114
2021 $0 $269 $68–$1,072 $132
2022 $124 $390 $100–$1,457 $149
2023 $1,203 $419 $114–$1,659 $160
2024 $2,859 $476 $123–$1,818 $164
2025 $2,729 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. GlaxoSmithKline, LLC. $1,873 62 payments
  2. AstraZeneca Pharmaceuticals LP $595 30 payments
  3. Actelion Pharmaceuticals US, Inc. $468 10 payments
  4. United Therapeutics Corporation $395 10 payments
  5. Electromed, Inc. $367 17 payments
  6. Regeneron Healthcare Solutions, Inc. $355 11 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $351 14 payments
  8. Genzyme Corporation $334 13 payments
  9. Amgen Inc. $326 17 payments
  10. Insmed, Inc. $318 11 payments
  11. Other $1,533 57 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $6,866 249 payments
  2. Education $50 3 payments
Products named General payments · program years 2022–2025
  1. NUCALA $1,222 29 payments
  2. TRELEGY ELLIPTA $626 32 payments
  3. UPTRAVI $468 10 payments
  4. OPSUMIT $444 9 payments
  5. SMARTVEST $367 17 payments
  6. TYVASO $362 9 payments
  7. DUPIXENT $334 13 payments
  8. TEZSPIRE $326 17 payments
  9. Arikayce $301 10 payments
  10. FASENRA $287 15 payments
  11. Other $2,662 103 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

998

Median for Pulmonary Disease: 936

Drug cost

$274,304

Median for Pulmonary Disease: $487,987

Branded share of claims

50.1%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 188 $139,314
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 60 $39,483
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 47 $26,358
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 38 $17,850
Breo Ellipta Fluticasone/Vilanterol Brand 44 $17,186
Spiriva Respimat Tiotropium Bromide Brand 28 $14,469
Symbicort Budesonide/Formoterol Fumarate Brand 27 $7,383
Azelastine Hcl Generic 194 $6,408
Fluticasone Propionate Generic 185 $2,836
Albuterol Sulfate Hfa Albuterol Sulfate Brand 52 $1,034

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$183,648

Medicare's payments for the services billed

Medicare patients

483

Average age 79

Services billed

2,226

275 women, 208 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 65%
COPD 60%
Arthritis 60%
Diabetes 54%
Heart failure 52%
Chronic kidney disease 48%
Atrial fibrillation 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
  • GlaxoSmithKline, LLC. $354
$354 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $312
$312 188 —
DUPIXENT
  • GENZYME CORPORATION $193
  • Regeneron Healthcare Solutions, Inc. $56
$249 — —
TYVASO
  • United Therapeutics Corporation $185
$185 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $170
$170 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

252 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record